
-
Man City close in on Champions League with Everton late show
-
14-year-old Vaibhav Suryavanshi becomes youngest IPL player
-
Barca make stunning comeback to beat Celta Vigo in Liga thriller
-
Zverev sets up birthday bash with Shelton in Munich
-
Man City boost top five bid, Southampton snatch late leveller
-
US Supreme Court intervenes to pause Trump deportations
-
Alcaraz and Rune race into Barcelona final
-
US, Iran to hold more nuclear talks after latest round
-
Man City close in on Champions League thanks to Everton late show
-
Bayern close in on Bundesliga title with Heidenheim thumping
-
Tunisia opposition figures get jail terms in mass trial
-
Putin announces 'Easter truce' in Ukraine
-
McLaren duo in ominous show of force in Saudi final practice
-
Afghan PM condemns Pakistan's 'unilateral' deportations
-
Iran says to hold more nuclear talks with US after latest round
-
Comeback queen Liu leads US to World Team Trophy win
-
Buttler fires Gujarat to top of IPL table in intense heat
-
Unimpressive France stay on course for Grand Slam showdown
-
Shelton fights past Cerundolo to reach Munich ATP final
-
Vance and Francis: divergent values but shared ideas
-
Iran, US conclude second round of high-stakes nuclear talks in Rome
-
Dumornay gives Lyon first leg lead over Arsenal in women's Champions League semis
-
Trans rights supporters rally outside UK parliament after landmark ruling
-
Rune destroys Khachanov to reach Barcelona Open final
-
From Messi to Trump, AI action figures are the rage
-
Vance discusses migration during Vatican meeting with pope's right-hand man
-
Afghan FM tells Pakistan's top diplomat deportations are 'disappointment'
-
British cycling icon Hoy and wife provide solace for each other's ills
-
Money, power, violence in high-stakes Philippine elections
-
Iran, US hold second round of high-stakes nuclear talks in Rome
-
Japanese warships dock at Cambodia's Chinese-renovated naval base
-
US Supreme Court pauses deportation of Venezuelans from Texas
-
Pakistan foreign minister arrives in Kabul as Afghan deportations rise
-
Heat and Grizzlies take final spots in the NBA playoffs
-
Iran, US to hold second round of high-stakes nuclear talks in Rome
-
Humanoid robots stride into the future with world's first half-marathon
-
Migrant's expulsion puts Washington Salvadorans on edge
-
Plan for expanded Muslim community triggers hope, fear in Texas
-
Pakistan foreign minister due in Kabul as deportations rise
-
White House touts Covid-19 'lab leak' theory on revamped site
-
Dodgers star Ohtani skips trip to Texas to await birth of first child
-
US senator says El Salvador staged 'margarita' photo op
-
Ford 'adjusts' some exports to China due to tariffs
-
Thomas maintains two-shot lead at RBC Heritage
-
US to withdraw some 1,000 troops from Syria
-
Four killed after spring storms wreak havoc in the Alps
-
Spurs' Popovich reportedly home and well after 'medical incident'
-
Trump goes to war with the Fed
-
Celtics chase second straight NBA title in playoff field led by Thunder, Cavs
-
White House site blames China for Covid-19 'lab leak'

Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
O.Krause--BTB